These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30042327)

  • 1. Challenges and Opportunities in the Management of Onychomycosis.
    Christenson JK; Peterson GM; Naunton M; Bushell M; Kosari S; Baby KE; Thomas J
    J Fungi (Basel); 2018 Jul; 4(3):. PubMed ID: 30042327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal Drug Use for Onychomycosis.
    Thomas J; Peterson GM; Christenson JK; Kosari S; Baby KE
    Am J Ther; 2019; 26(3):e388-e396. PubMed ID: 31082864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis.
    Tupaki-Sreepurna A; Jishnu BT; Thanneru V; Sharma S; Gopi A; Sundaram M; Jyoti Kindo A
    J Fungi (Basel); 2017 May; 3(2):. PubMed ID: 29371538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal agents for onychomycosis: new treatment strategies to improve safety.
    Zane LT; Chanda S; Coronado D; Del Rosso J
    Dermatol Online J; 2016 Mar; 22(3):. PubMed ID: 27136621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in therapies for onychomycosis and its management.
    Gupta AK; Stec N
    F1000Res; 2019; 8():. PubMed ID: 31297182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential Oils for Treatment for Onychomycosis: A Mini-Review.
    Flores FC; Beck RC; da Silva Cde B
    Mycopathologia; 2016 Feb; 181(1-2):9-15. PubMed ID: 26481920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for the treatment of onychomycosis.
    Gupta AK; Stec N
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):213-220. PubMed ID: 31652088
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug delivery to the nail: therapeutic options and challenges for onychomycosis.
    Barot BS; Parejiya PB; Patel HK; Mehta DM; Shelat PK
    Crit Rev Ther Drug Carrier Syst; 2014; 31(6):459-94. PubMed ID: 25271773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy.
    Elewski BE; Hay RJ
    Clin Infect Dis; 1996 Aug; 23(2):305-13. PubMed ID: 8842269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress on the topical therapy of onychomycosis.
    Alley MR; Baker SJ; Beutner KR; Plattner J
    Expert Opin Investig Drugs; 2007 Feb; 16(2):157-67. PubMed ID: 17243936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for the treatment of ungual onychomycosis.
    Kushwaha A; Murthy RN; Murthy SN; Elkeeb R; Hui X; Maibach HI
    Drug Dev Ind Pharm; 2015; 41(10):1575-81. PubMed ID: 25997365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections.
    Stasko N; McHale K; Hollenbach SJ; Martin M; Doxey R
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
    Gupta AK; Konnikov N; Lynde CW
    J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on photodynamic therapies in the treatment of onychomycosis.
    Simmons BJ; Griffith RD; Falto-Aizpurua LA; Nouri K
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1275-9. PubMed ID: 25589056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etiopathogenesis, clinical picture and diagnosis of onychomycoses].
    Tasić S; Stojanović S; Poljacki M
    Med Pregl; 2001; 54(1-2):45-51. PubMed ID: 11432322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging topical onychomycosis therapies - quo vadis?
    Elkeeb R; Hui X; Murthy N; Maibach HI
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):489-95. PubMed ID: 25401504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?
    Elewski BE; Cantrell W; Lin T
    J Drugs Dermatol; 2018 Feb; 17(2):175-178. PubMed ID: 29462225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for biofilms in onychomycosis.
    Gupta AK; Foley KA
    G Ital Dermatol Venereol; 2019 Feb; 154(1):50-55. PubMed ID: 29683287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.